NCT06617091View on ClinicalTrials.gov

A Phase 1 Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and with HIV

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 12, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions
HIV
Interventions
DRUG

GRAdHIVNE1 Vaccine

This is a dose ranging study that will allow for simultaneous enrollment of participants in both low and high dose groups.

OTHER

Placebo

This is a dose ranging study that will allow for simultaneous enrollment of participants in both low and high dose groups.

All Listed Sponsors
collaborator

Ragon Institute

UNKNOWN

collaborator

ReiThera Srl

INDUSTRY

collaborator

Mutala Trust

UNKNOWN

lead

International AIDS Vaccine Initiative

NETWORK